WALTHAM, Mass., Aug. 30, 2017 /PRNewswire/ -- Syndax
Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical stage
biopharmaceutical company developing entinostat and SNDX-6352 in
multiple cancer indications, today announced that Briggs W. Morrison, M.D., Chief Executive
Officer of Syndax, will participate in three upcoming investor
conferences. The details for the three conferences are:
- Citi's 12th Annual Biotech Conference at the Mandarin
Oriental in Boston, Massachusetts
on Wednesday, September 6, 2017.
Panel discussion at 9:00 am
ET.
- The Morgan Stanley 15th Annual Global Healthcare Conference
at the Grand Hyatt in New York
City on Monday, September 11,
2017. Fireside chat at 2:50 pm
ET.
- The Cantor Fitzgerald Global Healthcare Conference at the
InterContinental New York Barclay Hotel on Monday, September 25, 2017. Corporate
presentation at 8:00 am ET.
A live webcast of these presentations can be accessed from the
Investor section of the Company's website at www.syndax.com,
where a replay of the events will also be available for a limited
time.
About Syndax Pharmaceuticals, Inc.
Syndax is a clinical stage biopharmaceutical company developing
an innovative pipeline of cancer therapies. Our lead product
candidate, entinostat, which was granted Breakthrough Therapy
designation by the FDA following positive results from our Phase 2b
clinical trial, ENCORE 301, is currently being evaluated in a Phase
3 clinical trial for advanced hormone receptor positive, human
epidermal growth factor receptor 2 negative breast cancer. Given
its potential ability to block the function of immune suppressive
cells in the tumor microenvironment, entinostat is also being
evaluated in combination with approved PD-1 antagonists. Ongoing
Phase 1b/2 clinical trials combine entinostat with KEYTRUDA from
Merck & Co., Inc. for non-small cell lung cancer melanoma and
colorectal cancer; with TECENTRIQ® from Genentech, Inc.
for triple negative breast cancer; and with BAVENCIO®
from Pfizer Inc. and Merck KGaA, Darmstadt, Germany, for ovarian cancer. Our second
product candidate, SNDX-6352, is a monoclonal antibody that blocks
the CSF-1 receptor and may also block the function of immune
suppressive cells in the tumor microenvironment. SNDX-6352 is being
evaluated in Phase 1 clinical trials and is expected to be
developed to treat a variety of cancers.
Investor Contact
Melissa
Forst
Argot Partners
melissa@argotpartners.com
Tel 212.600.1902
Media Contact
Eliza Schleifstein
Argot Partners
eliza@argotpartners.com
Tel 973.361.1546
SNDX-G
View original
content:http://www.prnewswire.com/news-releases/syndax-pharmaceuticals-announces-participation-at-three-upcoming-investor-conferences-300511135.html
SOURCE Syndax Pharmaceuticals, Inc.